IMR Press / FBL / Volume 9 / Issue 5 / DOI: 10.2741/1442

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
Adult T cell leukemia lymphoma
Show Less
1 Division of Molecular Oncology Washington University School of Medicine St Louis, Missouri, USA
Academic Editor:Q. Ping Dou
Front. Biosci. (Landmark Ed) 2004, 9(5), 2852–2859; https://doi.org/10.2741/1442
Published: 1 September 2004
(This article belongs to the Special Issue Potential molecular targets for chemoprevention)
Abstract

Adult T cell leukemia lymphoma (ATLL) is a CD4+ lymphoproliferative malignancy resulting from human T-cell leukemia virus type 1 (HTLV-1) infection. It includes differing clinical forms classified as smoldering, chronic, lymphomatous, and acute ATLL. The Tax protein of HTLV-1 has been implicated as a viral oncoprotein which enhances virus replication and alters cellular gene expression, including activation of nuclear factor kappa B (NF kB), to result in lymphoid transformation. Chemotherapy for ATLL has had limited efficacy with median survivals of about 1 yr. Antiviral therapy employing zidovudine and interferon has shown promising results, as have antibody-based therapies to the interleukin 2 (IL2) receptor. Novel approaches employ a combination of chemo/antiretroviral therapy, hematopoietic stem cell transplantation, or inhibitors of NF kB activation.

Share
Back to top